PKO Investment Management Joint Stock Co Sells 1,500 Shares of Humana Inc. (NYSE:HUM)

PKO Investment Management Joint Stock Co lowered its holdings in shares of Humana Inc. (NYSE:HUM) by 42.9% during the 1st quarter, HoldingsChannel reports. The fund owned 2,000 shares of the insurance provider’s stock after selling 1,500 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Humana were worth $529,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of HUM. FPC Investment Advisory Inc. purchased a new position in shares of Humana during the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. Riverview Trust Co purchased a new position in Humana during the first quarter valued at $34,000. Finally, OFI Invest Asset Management bought a new stake in Humana in the fourth quarter worth $33,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

HUM has been the subject of several analyst reports. Barclays set a $268.00 price target on Humana and gave the company an “equal weight” rating in a report on Thursday, June 12th. Guggenheim started coverage on shares of Humana in a research report on Wednesday, April 9th. They set a “buy” rating and a $326.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Wall Street Zen downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial reduced their price target on shares of Humana from $305.00 to $280.00 and set a “hold” rating for the company in a research report on Tuesday. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $280.76.

Humana Stock Performance

HUM stock opened at $241.38 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a market cap of $29.13 billion, a P/E ratio of 17.07, a price-to-earnings-growth ratio of 1.78 and a beta of 0.43. The stock’s fifty day moving average price is $248.65 and its 200-day moving average price is $261.84.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. Humana’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $7.23 earnings per share. On average, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date is Friday, June 27th. Humana’s payout ratio is 25.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.